DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 908.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,748 shares of the medical device company's stock after acquiring an additional 57,427 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in DexCom were worth $4,274,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DXCM. Jennison Associates LLC boosted its stake in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares during the period. Legal & General Group Plc increased its holdings in DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock valued at $339,352,000 after buying an additional 49,076 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of DexCom by 11.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock worth $183,298,000 after buying an additional 288,381 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after purchasing an additional 353,019 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on DXCM shares. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Canaccord Genuity Group lifted their price objective on DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a research report on Monday. Wells Fargo & Company boosted their target price on shares of DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, October 25th. Oppenheimer lowered their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $101.88.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Up 0.9 %

DXCM traded up $0.69 during trading on Monday, hitting $78.41. 2,287,807 shares of the company's stock were exchanged, compared to its average volume of 3,899,327. The stock has a 50 day moving average price of $72.77 and a 200 day moving average price of $85.41. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market cap of $30.63 billion, a P/E ratio of 46.95, a price-to-earnings-growth ratio of 2.38 and a beta of 1.12.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.